| Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma J Larkin, PA Ascierto, B Dréno, V Atkinson, G Liszkay, M Maio, M Mandalà, ... New England Journal of Medicine 371 (20), 1867-1876, 2014 | 2465 | 2014 |
| Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial PA Ascierto, GA McArthur, B Dréno, V Atkinson, G Liszkay, ... The lancet oncology 17 (9), 1248-1260, 2016 | 1159 | 2016 |
| Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3 DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... Journal of Clinical Oncology 36 (24), 2465-2472, 2018 | 1050 | 2018 |
| Overall survival with ribociclib plus fulvestrant in advanced breast cancer DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... New england Journal of medicine 382 (6), 514-524, 2020 | 753 | 2020 |
| Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Annals of Oncology 32 (8), 994-1004, 2021 | 513 | 2021 |
| Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled … PA Ascierto, M Del Vecchio, M Mandalá, H Gogas, AM Arance, S Dalle, ... The Lancet Oncology 21 (11), 1465-1477, 2020 | 499 | 2020 |
| Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial JJ Luke, P Rutkowski, P Queirolo, M Del Vecchio, J Mackiewicz, ... The Lancet 399 (10336), 1718-1729, 2022 | 391 | 2022 |
| Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III … DJ Slamon, P Neven, S Chia, G Jerusalem, M De Laurentiis, S Im, ... Annals of oncology 32 (8), 1015-1024, 2021 | 240 | 2021 |
| Obesity and breast cancer: role of leptin F Sánchez-Jiménez, A Pérez-Pérez, L De la Cruz-Merino, ... Frontiers in oncology 9, 596, 2019 | 226 | 2019 |
| Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of … X Pivot, J Gligorov, V Müller, G Curigliano, A Knoop, S Verma, V Jenkins, ... Annals of oncology 25 (10), 1979-1987, 2014 | 196 | 2014 |
| Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety D Moreno-Ramirez, L Cruz-Merino, L Ferrandiz, R Villegas-Portero, ... The oncologist 15 (4), 416-427, 2010 | 179 | 2010 |
| Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402) JM Piulats, E Espinosa, L de la Cruz Merino, M Varela, L Alonso Carrión, ... Journal of Clinical Oncology 39 (6), 586-598, 2021 | 178 | 2021 |
| 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study PA Ascierto, B Dréno, J Larkin, A Ribas, G Liszkay, M Maio, M Mandalà, ... Clinical Cancer Research 27 (19), 5225-5235, 2021 | 147 | 2021 |
| Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden C Morrison, S Pabla, JM Conroy, MK Nesline, ST Glenn, D Dressman, ... Journal for immunotherapy of cancer 6, 1-12, 2018 | 146 | 2018 |
| nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results … DA Yardley, R Coleman, P Conte, J Cortes, A Brufsky, M Shtivelband, ... Annals of oncology 29 (8), 1763-1770, 2018 | 121 | 2018 |
| Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind … GV Long, JJ Luke, MA Khattak, L de la Cruz Merino, M Del Vecchio, ... The Lancet Oncology 23 (11), 1378-1388, 2022 | 106 | 2022 |
| Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative … DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... Annals of Oncology 30, v856-v857, 2019 | 104 | 2019 |
| Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915) JS Weber, D Schadendorf, M Del Vecchio, J Larkin, V Atkinson, ... Journal of Clinical Oncology 41 (3), 517-527, 2023 | 99 | 2023 |
| New insights into the role of the immune microenvironment in breast carcinoma L de la Cruz-Merino, A Barco-Sánchez, F Henao Carrasco, ... Journal of Immunology Research 2013 (1), 785317, 2013 | 97 | 2013 |
| Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors JM Conroy, S Pabla, MK Nesline, ST Glenn, A Papanicolau-Sengos, ... Journal for immunotherapy of cancer 7, 1-11, 2019 | 94 | 2019 |
